Nephroblastoma overexpressed gene (NOV) is highly expressed in the nervous system. We investigated its biological activity by expressing the human NOV gene (NOVH) in a human glioblastoma cell line that is negative for NOVH and by analyzing four clones with different levels of NOVH expression. There was no difference in cell proliferation between the NOVHexpressing cell lines, but there was increased cell adhesion and migration that correlated with increasing NOVH expression. Gene expression profiling was used to investigate the mechanisms by which NOVH expression regulated cell activity. We identified two induced genes in NOVHexpressing cells that are involved in cell migration: matrix metalloprotease (MMP)3 and plateletderived growth factor receptor (PDGFR)-α. Our studies show that PDGFR-α induced MMP3 gene expression and increased cell proliferation and cell migration upon stimulation by plateletderived growth factor (PDGF)-AA. We also show that the induction of MMP3 in cells expressing NOVH is potentiated by either cell density, serum, or PDGF-BB. Thus, expression of NOVH in glioblastoma cells triggers a cascade of gene expression resulting in increased cell adhesion and migration.
The NOV protein is detected at different levels in the kidney, muscle, cartilage, brain, lung, ovary, and heart. The adrenal cortex is the major endocrine site of novH expression (3, (14) (15) (16) . In normal tissues, the expression of NOV is tightly regulated with development, which suggests that it is involved in cell differentiation and in tissue/organ development. The expression of NOV correlates with the formation of cartilage and depends on the differentiation of chondrocytes (M. Laurent, unpublished results). Therefore, as shown for CTGF and CYR61 (17, 18) , NOV may play a role in chondrogenesis. Muscles are also a site of NOV expression, and recent data reported that an elevated expression of NOV resulted in an inhibition of the differentiation of myogenic cells into myotubes (19, our unpublished results) . In all tumors derived from tissues that normally express NOV, alterations of its expression have been observed. Thus, the different expression profiles of NOV in various tumors indicate that NOV may also influence tumor progression (9, 14, 16, (20) (21) (22) (23) . Therefore, NOV appears to play important roles in development, in the formation of several tissues, and in tumorigenesis. However, the mechanisms of its functions are still largely unknown, and in particular, the genes regulated by NOV have not been identified.
The central nervous system (CNS) is a site of high NOV expression. In adult rats, NOV is highly expressed in the cortex and in the hippocampus (24, and our unpublished data). In human and rat, the nov gene is regulated during the development of the CNS and a high NOV expression is associated with CNS development (3, (24) (25) (26) . In vitro, NOV is produced by primary cultures of mouse astrocytes (8) and human glioblastoma cell lines established from astrocytomas and glioblastomas (27) expressed different levels of NOV (28, 29) . The function and the mechanisms of action of NOV in the CNS remain unknown. To clarify the role of NOVH in glial cells, we established human glioblastoma cell lines expressing NOV at different levels, examined the effect of increased expression of NOVH on the biology of glioblastoma cells, and characterized the genes regulated by NOVH, using gene profiling. We demonstrate that increased expression of NOVH stimulates the adhesion and the migration of glioblastoma cells and increases the expression of the matrix metalloprotease (MMP)3 and platelet-derived growth factor receptor (PDGFR)-α genes.
MATERIALS AND METHODS

Cell transfections and isolation of stable transfectant clones
G59 glioblastoma cells were transfected with 6 µg pCMV NOVH (S) or (AS) plasmid DNA in the presence of lipofectamine (Life Technologies, Grand Island, NY). Transfected cells were selected with G418 (300 µg/ml) in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Isolated clones were picked and expanded, and their NOVH expression was studied by Northern analysis and Western blotting.
Western blotting
Total protein was solubilized from cell lysates in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.05% sodium deoxycholate, 1% NP-40, 5 mM EDTA) containing 5 mg/ml each of leupeptin, antipain, chymostatin, and pepstatin; 0.4 TIU/ml (trypsin inhibiting units) of aprotinin; and 2 mM of aminoethylbenzenesulfonyl fluoride. The proteins in the conditioned media were concentrated by the addition of 0.05% deoxycholate and 7% trichloracetic acid. The proteins were mixed with Laemmli buffer, electrophoresed on a 12% polyacrylamide gel containing SDS, and electroblotted onto a PVDF filter (Hybond P, Pharmacia-Amersham, Orsay, France). The membranes were incubated for 1 h at 37°C with either affinity purified NOVH K19M polyclonal antibody (14) , MMP3, or MMP2 monoclonal antibodies (Oncogene Research), or PDGFR-α or PDGFR-β polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). After incubation with anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase (Sigma, St. Louis, MO), the immunoreactive proteins were detected by enhanced chemiluminescence (ECL) according to the manufacturer's instructions (Pharmacia-Amersham).
Northern blotting
Total RNA was prepared using the Tri-Reagent method (Sigma) according to the manufacturer's instructions. RNA (15 µg) was electrophoresed in denaturing formaldehyde 1% agarose gels. The RNA was transferred to a nylon membrane (Pharmacia-Amersham), and the membrane was hybridized at 42°C for 18 h with a 32 P probe labeled by random hexamer priming (PharmaciaAmersham). The membrane was washed and the radioactive signals were digitized using a Phospho-Imager and quantified.
Cell proliferation
Proliferation was assessed by cell counting and by 3 H-thymidine incorporation. Cells were plated at a density of 10 4 cells per 35-mm well, starved for 18 h in DMEM containing 0.5% FCS, treated for 8 h with PDGF-AA and PDGF-BB (10 ng/ml), and pulse-labeled for 2 h with 1 µCi/ml of 3 H-thymidine. After washing with PBS, 5% TCA was added to each well for 15 min at 4°C. Total incorporated 3 H-thymidine was counted after complete cell dissolution at 37°C for 2 h in 0.5 M NaOH.
Migration assays
Migration was assayed after 24 h in a modified Boyden chamber with polycarbonate PVPF (Osmonics, Inc.) filters with 12-µm pores. Filters were coated at room temperature for 1 h with 0.1 µg/ml of fibronectin. Cells (3×10 4 ) were added to the upper chamber in 50 µl of DMEM containing 0.1% bovine serum albumin (BSA). The lower chamber wells were filled with 30 µl of DMEM in the presence of PDGF-AA, PDGF-BB (10 ng/ml, unless otherwise indicated in the text), or 1µg of laminin-1 as a chemoattractant. In some experiments, migration was inhibited by the addition to both chambers of either 2.5 mM EDTA or 100 nM of the metalloprotease inhibitor GM6001. After an overnight incubation at 37°C, cells were fixed with 4% formaldehyde in PBS and stained with Giemsa. Cells on the upper side of the filter were removed and the cells on the lower side of the filter were counted. Ten visual fields from three different wells were counted per experiment. For the scratch assay, confluent cells were scraped using a pipette tip. After 18 h, the plates were fixed and visualized after staining with Giemsa.
Recombinant NOVH protein production
For protein production, Sf9 cells were infected with NOVH recombinant baculovirus for 72 h. Conditioned medium containing 1% FCS was clarified by centrifugation, and NOVH recombinant proteins were purified by Ni-NTA-agarose affinity chromatography after two sequential precipitations with (NH4) 2 S0 4 at 75% saturation, essentially as described previously (30) . Recombinant NOVH proteins eluted with 125 mM imidazole, pH 7.5, were pooled, and further purified by chromatography on Cibacron-Blue TSK columns (Toyopearl) previously equilibrated in 100 mM phosphate buffer (pH 7.2). Washes and elution were conducted in the same buffer containing 0.3 M NaCl and 0.8 M NaCl, respectively. NOVH protein-containing fractions were desalted on a PD10 column (Pharmacia) and equilibrated with 30 mM ammonium acetate, and eluted proteins were lyophilized, resuspended in PBS containing 10% glycerol, and stored at -80°C. The purity of recombinant NOVH was assessed by SDS-PAGE.
Cell adhesion
Ninety-six-multiwell plates were coated with 10 µg/ml of either fibronectin, BSA, 0.01% collagen type I, or 20 µg/ml of poly-L-lysine after an overnight incubation at 4°C. After washings with PBS, plates were saturated with 0.1% BSA in PBS for 1 h at 37°C. Cells were plated at a density of 60,000 cells per well. After 1 h, the medium was replaced by DMEM containing 500 µg/ml of MTT, and the wells were further incubated for 3 h. Formazan precipitates were then dissolved by the addition of 1 volume of isopropanol in 0.05 N HCl. The absorbance was measured at 570 and 690 nm using a Tecan ELISA plate reader.
Gene profiling
Total RNA was obtained using a Nucleospin kit (Clontech, San Diego, CA) from clones transfected with either the sense or the antisense NOVH recombinant plasmids. Radioactive cDNA synthesis was carried out as described in the Atlas cDNA expression arrays user manual. Equal amounts of radiolabeled cDNAs were hybridized in parallel to two Atlas 1.2I and 1.2II expression arrays for 18 h at 68°C. After washing, the membranes were exposed to Kodak phosphor screens for 2-3 days. Hybridization signals were quantified with a Storm phosphoimager (Molecular Dynamics, Sunnyvale, CA), using the Image Quant software (Amersham Pharmacia Biotech, Piscataway, NJ) and normalized against GAPDH (glyceraldehyde-3-phosphate dehydrogenase). Significance of induction or inhibition of gene expression was set at twofold.
RT-PCR and probes specific for PDGFR-α and MMP3
Total RNA (50 ng) was reverse transcribed and PCR amplified using SuperScript One-Step RT-PCR (Life Technologies) according to the manufacturer's instructions. The PCR products were purified with the QIAquick PCR purification kit and sub-cloned onto the PGEM-T vector using the PGEM-T vector system (Life Technologies) according to the manufacturer's instructions and were sequenced.
Luciferase reporter assays
The MMP3-Luc promoter construct was derived from MMP3-CAT (31) (chloramphenicol acetyl-transferase) following an EcoRI-Hind III digestion and subcloning the MMP3 promoter sequence (-2311 to -11) into the promoter-less p2KM (BT) luciferase vector (32) .
G59 glioblastoma cells (2×10
5 ) in six-well plates were transfected using Lipofectamine Plus (Life Technologies) with the reporter construct (0.5 µg) and with 0.1 µg of pCMV β-galactosidase as an internal transfection control. In some experiments, following the transfection, the cells were treated with either fibrobalst growth factor (FGF)2 (10 ng/ml) or PDGF-BB (40 ng/ml). Luciferase and β-galactosidase activities were assayed using kits from Promega (Madison, WI) and Perkin Elmer (Galacto-star system; Norwalk, CT), respectively. Each data point was performed in triplicate, and the data are expressed as the mean ± SE. Two independent experiments gave the same results.
RESULTS
Isolation and characterization of NOVH-expressing and non-expressing glioblastoma cells
To probe the function of NOVH, we transfected the G59 glioblastoma cell line, which is negative for NOVH, with sense and anti-sense NOVH recombinant plasmids. Pools of transfectants were selected in G418. After immunostaining for NOVH (14) , three sense transfected clones, N1, N2, and N3, which showed different staining intensities for NOVH, and one anti-sense transfected clone, N4, were selected for further study (data not shown). N4 was used as a NOVH-negative control. The expression of NOVH in these clones was further characterized at the protein and mRNA levels (Fig. 1A, 1B ). Various amounts of the full-length NOVH protein were detected in the cell lysates and in the conditioned media (Fig. 1A) . The Nterminal truncated NOVH isoform (14) could only be detected after being concentrated from the conditioned media by heparin-sepharose affinity chromatography (data not shown). The NOVHpositive clones expressed different levels of NOVH mRNA, which correlated with the amounts of NOVH protein detected by Western blot (Fig. 1B) . The control antisense selected cells, like the parental cells, did not express NOVH protein or mRNA.
Effect of NOVH on the adhesion of glioblastoma cells
NOVH interacts with fibulin-1C, an extracellular matrix protein (33) , and promotes the adhesion of cells (13) . We tested whether the expression levels of NOVH could influence cell adhesion to poly-L-lysine, laminin, and fibronectin. An increase in the adhesion of the NOVH-expressing cells was observed on poly-L-lysine ( Fig. 2A ) and on laminin (Fig. 2B ). On fibronectin (Fig. 2C) , this increase was only observed for the clones expressing the highest levels of NOVH. However, adhesion of the G59 glioblastoma cells was not affected when recombinant full-length NOVH protein was coated on the wells (Fig. 2D ) and when the assay was performed in the presence of conditioned media containing 150 ng/ml of NOVH (data not shown). These data suggest that NOVH is not a cell adhesion molecule but may regulate proteins directly or indirectly involved in glioblastoma cell adhesion.
Effect of NOVH on the migration of glioblastoma cells in vitro
The effect of NOVH on cell migration was tested using the scratch monolayer assay and the Boyden chamber assay. In the scratch assay, the cells expressing NOVH migrated faster than the NOVH nonexpressing control cells (data not shown). This was confirmed by analysis of cell migration in the Boyden chamber on fibronectin-coated filters (Fig. 3A) . The cells expressing high levels of NOVH (N1 and N2) migrated three-to eightfold more than the control (N4) cells, whereas a twofold increase was found for cells expressing a lower level of NOVH (N3). The migration of the N1-transfected cells was completely inhibited when the assay was performed in the presence of 2.5 mM EDTA (Fig. 3B) . Furthermore, the metalloprotease inhibitor GM6001 reduced migration by ∼80% (Fig. 3B ). These data demonstrate that NOVH is involved in promoting cell migration and that this migration is protease-dependent.
Gene profiling
Gene profiling was used to identify the genetic mechanisms by which NOVH regulate cell activity. RNA from NOVH-expressing and control cells was hybridized to filters containing 1176 known genes. Two genes were both up-regulated fourfold by NOVH: MMP3, a member of the metalloprotease family, and the PDGF-α receptor, also known to be a powerful regulator of MMP3 gene expression (34) . The observed differences in MMP3 and PDGFR-α were confirmed at the RNA and protein levels in the three NOVH-expressing clones.
Using semiquantitative RT-PCR and Northern blotting, MMP3 and PDGFR-α were increased in the three NOVH-expressing cells (Fig. 4A ). Densitometric analysis of Northern blots revealed for the N1 cells a 3.6-and a 35-fold increase in MMP3 and PDGFR-α, respectively. Therefore, NOVH expression in G59 cells increases the expression of MMP3 and PDGFR-α genes (Fig.  4B, 4C ).
The amounts of PDGFR-α and MMP3 proteins were examined by Western blot analysis. In the three NOVH expressing clones, PDGFR-α was increased four-, three-, and twofold for the N1, N2, and N3 cells, respectively, when compared with control cells, whereas no change was detected for PDGFR-β (Fig. 5A , 5B). To test the functional signaling activity of increased PDGFR-α expression, we stimulated NOVH-expressing and control cells with PDGF-BB for 7 and 15 min and probed with a phospho-tyrosine antibody. The phosphorylation of a 160-kDa protein was increased twofold in the NOVH-expressing cells, but no change was detected in the control non-NOVH-expressing cells (Fig. 5C ). This phophorylated protein also reacted with a PDGFR-α-specific antibody (data not shown).
Because there are differences in PDGFR-α and -β in their binding specificity of ligands and in the signals they tranduce, increased expression of the PDGFR-α could be important in enhancing the mitogenic and chemotactic responses of glioblastoma cells to PDGF-AA and PDGF-BB. The PDGF-AA, which only binds the PDGFR-α, increased the migration of the cells expressing high levels of NOVH (N1), had a moderate effect on the cells expressing a lower level of NOVH (N3) (Fig. 6A ) and had no effect on the non-NOVH-expressing cells (N4). PDGF-BB stimulation of high NOVH-expressing cells (N1) also resulted in an increased cell migration, but to a lower extent than PDGF-AA, and had no effect on the low NOVH-expressing cells (N3). The PDGF-AA-induced NOVH-cell migration was dose-dependent (Fig. 6B) . The proliferation of clones expressing different amounts of NOVH and of the control clone was examined by 3 H-thymidine incorporation in the presence of PDGF-AA and PDGF-BB (Fig. 6C ). In the absence of PDGF, 3 H-thymidine incorporation was identical in the high NOVH-expressing cells (N1,) the low NOVH-expressing cells (N3), and the control cells (N4). This suggested that NOV is not involved in the control of G59 glioblatoma cell proliferation. This was confirmed by cell counting over 7 days of culture (data not shown). However, the presence of the increased PDGFR-α in the high NOVH-expressing cells resulted in increased 3 H-thymidine incorporation in the PDGF-AA-stimulated cells and to a lower extent, in the PDGF-BB stimulated cells, whereas neither PDGF-AA nor PDGF-BB stimulated 3 H-thymidine incorporation in the low NOVH-expressing cells (N3) and in the control cells (N4). These data demonstrate that NOVH increases both the expression and functional activity of PDGFR-α.
Analysis of MMP3 by Western blot showed a sixfold increase in the N1 and N2 cells and a twofold increase in the N3 cells compared with control cells (Fig. 7A) . In contrast, the amounts of MMP2 were not significantly different in the cell lines irrespective of NOVH protein levels. A positive correlation between the MMP3 levels and NOVH levels suggests that NOVH may induce the expression of MMP3. This was confirmed by analysis of MMP3 and MMP2 levels in cells treated for 24 and 72 h with full-length and N-truncated NOVH recombinant proteins. A 3.6-fold specific increase of MMP3 was observed when cells were treated for 72 h with the fulllength NOVH. Again, no effect on the expression of MMP2 was observed. The N-truncated NOVH isoform had no effect on either of the metalloproteases (Fig. 7B ). These data demonstrate that both endogenous and exogenous NOVH induces MMP3 expression. Because it took 72 h for the protein levels to increase, an indirect downstream effect of NOVH on MMP3 synthesis is suggested.
Regulation of MMP3 by cell density, serum, and growth factors in NOVH-expressing cells
The amount of MMP3 mRNA in NOVH-expressing cells and in control cells was evaluated as a function of cell density and in presence of serum. In control cells, two-and sixfold increases in MMP3 mRNA were observed when the cell density increased from 0.12 to 0.5 and to 2.7 × 10 3 cells/cm 3 , respectively. For N1 and N2 NOVH-expressing cells, an eight-and fourfold increase, respectively, was observed when the cell density increased from 0.12 to 0.5 × 10 3 cells/cm 3 (Fig. 8B) . The effect of serum on the expression of MMP3 mRNA by NOVHexpressing cells was also examined. In the presence of FCS, N1 and N2 NOVH-expressing cells increased 4-and 2.4-fold, respectively, in MMP3 mRNA levels over that observed with cells cultured without serum. Serum had no effect on the amount of MMP3 mRNA expressed by control cells (Fig. 8C) . The effect of NOVH on the expression of MMP3 was specific, because the amount of MMP2 expressed in control and in NOVH-expressing cells was similar and was not affected by serum. These data suggest that regulation of MMP3 expression by NOVH is potentiated by factors produced by confluent glioblastoma cells cultured with serum.
To identify the factors regulating MMP3 expression that are potentiated by NOVH, NOVHexpressing (N1 and N2) and control cells (N4) were treated with epidermal growth factor (EGF), FGF2, PDGF-BB, and TGFβ1. EGF and FGF2 increased and TGFβ1 decreased the amount of MMP3 regardless of the level of NOVH expression (Fig. 9A) . However, PDGF-BB was the only growth factor to increase the amount of secreted MMP3, in both cell lines expressing NOVH but not in the control cells. The effect was specific because the amount of MMP2 was unchanged in all the cell lines treated with any growth factor (Fig. 9B) . The control (N4) and NOVHexpressing cells (N1) were treated with tyrphostin AG1295, which selectively inhibits PDGFR-α autophosphorylation stimulated by PDGF-BB. In the presence of AG1295, the amount of MMP3 secreted by the NOVH-expressing cells was significantly reduced (Fig. 9C) . We next examined the effects of PDGF-BB and FGF2 on MMP3 promoter activity. NOVH-expressing (N1) and control cells (N4) were transfected with a MMP3 promoter construct and then stimulated with PDGF-BB and with FGF2 for 24 h. As shown in Figure 9C , FGF2 stimulated MMP3 promoter activity in both cell lines. In contrast, MMP3 promoter activity was significantly stimulated by PDGF-BB only in cells expressing NOVH and with no effect on control cells. Similar data were obtained with the two other NOVH-expressing clones (data not shown). These data show that both FGF2 and PDGF-BB can induce MMP3 promoter expression, but PDGF-BB plays a specific role in NOVH-expressing cells by increasing MMP3 promoter activity and protein secretion.
DISCUSSION
The CNS is a major site of NOVH expression (3, 8, 24-26, 28, 29) . The temporal and spatial expression of NOV suggests that NOVH plays a role in the development of the CNS. To establish the biological function of NOVH in glial cells, we profiled gene expression in glioblastoma cells positive and negative for NOVH and report the first identification of genes regulated by NOVH. We show that NOVH induced PDGFR-α and MMP3: two genes important for brain development and in brain tumor progression.
In transfected glioblastoma cells, NOVH induces the expression of MMP3 in a dose-dependent manner. The increase is potentiated by the presence of serum, and the induction of MMP3 requires 72 h with recombinant NOVH protein. These data indicate that NOVH indirectly regulates MMP3. This is confirmed by the fact that we failed to induce MMP3 promoter activity in transiently transfected cells treated with recombinant NOVH protein or co-transfected with a CMV-NOVH-expressing plasmid (data not shown). We also show that EGF, FGF2, and TGFβ1 regulated MMP3 expresssion in glioblastoma cells independently of NOVH expression. In contrast, PDGF-BB stimulated MMP3 promoter activity and increased the amount of secreted MMP3 in cells expressing NOVH, whereas control cells did not show an effect. In addition, the specific inhibition of the PDGFR-α resulted in a partial abolition of the MMP3 induction. These data indicate that MMP3 is not a direct target of NOVH and suggest that its induction in the NOVH-transfected cells is mediated by overexpression of PDGFR-α with subsequent increased signaling. MMP3 gene expression is regulated by inflammatory cytokines, oncogenes, and mitogens. PDGF is a potent inducer of MMP3 in several cell systems (34) . In NIH 3T3 cells, the signal induced by PDGF depends on Ras and involves two pathways: one pathway depends on Raf-1 and activates the MMP3 promoter via the AP1 and PEA3 elements, and the other involves PKC isoforms that act via the AP1 and SPRE elements (35) .
NOVH is not the only member of the CCN family to activate MMPs. In matrix remodeling, CTGF induced the expression of MMP2 in vascular smooth muscle cells, suggesting a new mechanism for the migration of these cells (36) . MMP1 and MMP2 are also induced by fibroblast adhesion to CYR61 and CTGF. Cell adhesion on these substrates was mediated through the integrin α6β1 (37) . We show that the expression of NOVH increased the adhesion of glioblastoma cells, whether this adhesion regulates MMP3 induction via the integrin receptors or whether the induction of MMP3 is mainly mediated via PDGFR-α signaling remains to be established. Therefore, the CCN proteins may regulate the MMPs via several mechanisms, including integrins and GFRs.
MMP3 is active on a broad range of substrates. It degrades noncollagenous matrix components, can inactivate serine protease inhibitors, and can activate other pro-metalloproteases more active on interstitial collagens. Thus, a proteolytic cascade of the extracellular matrix is created that facilitates cell migration. The levels of migration correlate with the level of NOVH expressed, and a protease inhibitor blocks NOVH-induced cell migration. Our data suggest that NOVH promotes cell migration via induced MMP3 expression. We also show that the increased migration of the NOVH-expressing cells is potentiated by the activation of the PDGFR-α by PDGF-AA or to a lower extent by PDGF-BB. The high level of PDGFR-α in high NOVHexpressing cells also resulted in increased cell proliferation upon stimulation by PDGF-AA and to a lower extent by PDGF-BB, whereas there was no correlation between the amount of expressed NOVH and cell proliferation, which indicates that NOVH is not directly involved in the control of G59 glioblastoma cell proliferation. The effect of NOVH on cell proliferation, therefore, appears to depend on the cell type. NOVH has a positive effect on the proliferation of Balb 3T3 cells (7) and negatively regulates chicken embryonic fibroblast proliferation (3). In different cell systems, the cascade of intracellular signaling events triggered by PDGF results in enhanced cell migration and proliferation, and it has been reported that growth factors and integrins may act in synergy (38) . PDGFR-β and the α V β 3 integrin associate to play a positive role in the migration of microvascular endothelial cells (39) . Similarly, upon PDGF-AA exposure of oligodendrocyte progenitors, a physical association between PDGFR-α and α V β 3 has been demonstrated, and the growth factor-mediated integrin activation is a critical integrative step in proliferation, differentiation, and migration of oligodendrocyte progenitors (40) . Whether there is an association between PDGFR-α and the integrins involved in the migration of the glioblastoma cells remains to be established.
Characterization of MMP3 and PDGFR-α as targets of NOV highlight others functions in which NOV may be involved. A very recent study showed that the CCN protein CTGF interacts with VEGF and that CTGF is degraded in the CTGF-VEGF complex by MMP3 (41, 42) . This results in a release of VEGF and in angiogenic activity. It is therefore conceivable that NOV, which activates the expression of MMP3, may contribute to the disruption of the CTGF-VEGF complex. As such, NOV could be involved as a positive regulator of the angiogenesis that occurs during the remodeling of the CNS and of the growth plate and in wound healing processes in which NOV and CTGF are co-expressed with VEGF and the MMPs. NOV and CTGF are two CCN genes regulated in an opposite manner and, therefore, they could be involved in antagonist activities. The induction of MMP3 by NOV may be one mechanism by which NOV could antagonize CTGF activity.
PDGFR-α is expressed in glial precursors in various regions of the developing CNS and in O2-A oligodendroglial-astroglial precursors (43) (44) (45) . Several in vitro studies suggest an important role for PDGF signaling in the differentiation of the O2-A glial progenitors that gives rise to either oligodendrocytes or type 2 astrocytes. In vivo, NOV is expressed in the neuronal tube, in the ventral horn of the spinal cord, and in the neurons and the astrocytes of the brain, which are all expression sites of PDGFR-α and of the cognate ligands. The overlapping expression of NOV, PDGFR-α, and PDGF ligands and our data showing that NOV regulates the expression of the PDGFR-α in glial cells suggest a functional role of NOV in the development and functional properties of the brain and spinal cord and in the differentiation of the O2-A cell progenitors.
Several studies have reported that the expression of NOVH is altered in most tumors derived from sites of its expression (14, 16) . Data showing an inverse correlation between the tumorigenicity of glioblastoma cell lines and their levels of NOVH expression suggested that NOVH could be a tumor suppressor gene and that it might be involved in the progression of astrocytoma to more malignant glioblastoma multiforme (27) . PDGFR-α and MMP3 are two genes important in the formation and development of brain tumors. MMPs are invariably upregulated in cancers and contribute to tumor invasion and metastasis (33) . Induction of PDGFR-α is likely to be an early event in glioma formation. However, despite the fact that in vitro cell migration of glioblastoma cells expressing NOVH is stimulated, we did not find that NOVHexpressing cells formed faster growing tumors in the athymic mice (data not shown). In fact, we found that the cells transfected with NOVH were unable to form tumors, whereas the parental cells and the antisense transfectants did form tumors. These data suggest that tumor growth is complex and that the induction of MMP-3 and PDGFR-α are not sufficient for tumor growth. MMPs alter cell-cell contacts, cell-extracellular matrix interactions, and release bioactive molecules and growth factors from the extracellular matrix, which in turn may alter the expression of other genes involved in the control of tumorigenesis. Therefore, the release by MMP3 of factors inhibiting the development of tumors and/or the regulation by NOVH of other genes, yet to be identified, may explain the absence of tumors.
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